> Exagen Diagnostics has filed plans to raise up to $69 million in an initial public offering. Story
> Genetic tests that identify mutations that may point to cancer risk are outpacing the understanding of what they mean. Story (sub. req.)
> The Washington state life sciences industry has surpassed $1 billion in transactions, including going public, acquisitions and licensing deals. Story
> Researchers have developed a biosensor made from graphene that can identify biomarkers pointing to an increased risk of developing cancer. Item
> The FDA has formally announced an emergency-use authorization for an in vitro diagnostic device to detect the Ebola virus. Notice